 | • レポートコード：MRC2304L076 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、223ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に9,872.31百万ドルであった世界のがん/腫瘍プロファイリング市場規模が、2022年に11,656.24百万ドルへと拡大し、その後CAGR 18.32％で成長して2027年までに27,094.28百万ドルに達すると予測しています。当書は、がん/腫瘍プロファイリングの世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、技術別（免疫学的検査、in-situハイブリダイゼーション、質量分析、マイクロアレイ、次世代シーケンシング）分析、がん種類別（乳がん、大腸がん、肺がん、メラノーマ、前立腺がん）分析、バイオマーカー種類別（ゲノムバイオマーカー、タンパク質バイオマーカー）分析、用途別（バイオマーカー発見、臨床応用、診断、個別化医療、予後）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめています。なお、当書に掲載されている企業情報には、Agendia, Inc.、Boreal Genomics Inc、Caris Life Sciences、Foundation Medicine、Genomic Health Inc.、GenScript Biotech Corporation、Guardant Health, Inc.、Helomics Corporation、HistoGeneX NV、HTG Molecular Diagnostics, Inc.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のがん/腫瘍プロファイリング市場規模：技術別 - 免疫学的検査の市場規模 - in-situハイブリダイゼーションの市場規模 - 質量分析の市場規模 - マイクロアレイの市場規模 - 次世代シーケンシングの市場規模 ・世界のがん/腫瘍プロファイリング市場規模：がん種類別 - 乳がんの市場規模 - 大腸がんの市場規模 - 肺がんの市場規模 - メラノーマの市場規模 - 前立腺がんの市場規模 ・世界のがん/腫瘍プロファイリング市場規模：バイオマーカー種類別 - ゲノムバイオマーカーの市場規模 - タンパク質バイオマーカーの市場規模 ・世界のがん/腫瘍プロファイリング市場規模：用途別 - バイオマーカー発見における市場規模 - 臨床応用における市場規模 - 診断における市場規模 - 個別化医療における市場規模 - 予後における市場規模 ・世界のがん/腫瘍プロファイリング市場規模：地域別 - 南北アメリカのがん/腫瘍プロファイリング市場規模 アメリカのがん/腫瘍プロファイリング市場規模 カナダのがん/腫瘍プロファイリング市場規模 ブラジルのがん/腫瘍プロファイリング市場規模 ... - アジア太平洋のがん/腫瘍プロファイリング市場規模 日本のがん/腫瘍プロファイリング市場規模 中国のがん/腫瘍プロファイリング市場規模 インドのがん/腫瘍プロファイリング市場規模 韓国のがん/腫瘍プロファイリング市場規模 台湾のがん/腫瘍プロファイリング市場規模 ... - ヨーロッパ/中東/アフリカのがん/腫瘍プロファイリング市場規模 イギリスのがん/腫瘍プロファイリング市場規模 ドイツのがん/腫瘍プロファイリング市場規模 フランスのがん/腫瘍プロファイリング市場規模 ロシアのがん/腫瘍プロファイリング市場規模 ... - その他地域のがん/腫瘍プロファイリング市場規模 ・競争状況 ・企業情報 |
The Global Cancer/Tumor Profiling Market size was estimated at USD 9,872.31 million in 2021 and expected to reach USD 11,656.24 million in 2022, and is projected to grow at a CAGR 18.32% to reach USD 27,094.28 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Cancer/Tumor Profiling to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Technology, the market was studied across Immunoassays, In-Situ Hybridization, Mass Spectrometry, Microarrays, Next-Generation Sequencing, Others, and Polymerase Chain Reaction.
Based on Cancer Type, the market was studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma Cancer, Other, and Prostate Cancer.
Based on Biomarker Type, the market was studied across Genomic Biomarker and Protein Biomarker.
Based on Application, the market was studied across Biomarker Discovery, Clinical Application, Diagnostics, Personalized Medicine, Prognostics, Research, Screening, and Treatment & Monitoring.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cancer/Tumor Profiling market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer/Tumor Profiling Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer/Tumor Profiling Market, including Agendia, Inc., Boreal Genomics Inc, Caris Life Sciences, Foundation Medicine, Genomic Health Inc., GenScript Biotech Corporation, Guardant Health, Inc., Helomics Corporation, HistoGeneX NV, HTG Molecular Diagnostics, Inc., Illumina, Inc., NanoString Technologies, Inc., NeoGenomics Laboratories, Inc., Omniseq, Inc., Perthera, Inc., QIAGEN N.V., Ribomed Biotechnologies, Inc., Roche Diagnostics, Sysmex Corporation, and Tempus Labs.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Cancer/Tumor Profiling Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer/Tumor Profiling Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer/Tumor Profiling Market?
4. What is the competitive strategic window for opportunities in the Global Cancer/Tumor Profiling Market?
5. What are the technology trends and regulatory frameworks in the Global Cancer/Tumor Profiling Market?
6. What is the market share of the leading vendors in the Global Cancer/Tumor Profiling Market?
7. What modes and strategic moves are considered suitable for entering the Global Cancer/Tumor Profiling Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising funding from government for devising cancer diagnosing methods
5.1.1.2. Increasing incidence of cancer
5.1.1.3. Increasing use of biomarkers in cancer profiling
5.1.2. Restraints
5.1.2.1. High capital investment in Cancer/Tumor Profiling devices
5.1.3. Opportunities
5.1.3.1. Increasing demand for personalized medicine
5.1.3.2. Growing need for point-of-care diagnostics
5.1.4. Challenges
5.1.4.1. Low biomarker discovery-to-approval ratio
5.2. Cumulative Impact of COVID-19
6. Cancer/Tumor Profiling Market, by Technology
6.1. Introduction
6.2. Immunoassays
6.3. In-Situ Hybridization
6.4. Mass Spectrometry
6.5. Microarrays
6.6. Next-Generation Sequencing
6.7. Others
6.8. Polymerase Chain Reaction
7. Cancer/Tumor Profiling Market, by Cancer Type
7.1. Introduction
7.2. Breast Cancer
7.3. Colorectal Cancer
7.4. Lung Cancer
7.5. Melanoma Cancer
7.6. Other
7.7. Prostate Cancer
8. Cancer/Tumor Profiling Market, by Biomarker Type
8.1. Introduction
8.2. Genomic Biomarker
8.3. Protein Biomarker
9. Cancer/Tumor Profiling Market, by Application
9.1. Introduction
9.2. Biomarker Discovery
9.3. Clinical Application
9.4. Diagnostics
9.5. Personalized Medicine
9.6. Prognostics
9.7. Research
9.8. Screening
9.9. Treatment & Monitoring
10. Americas Cancer/Tumor Profiling Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Cancer/Tumor Profiling Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Cancer/Tumor Profiling Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Agendia, Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Boreal Genomics Inc
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Caris Life Sciences
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Foundation Medicine
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Genomic Health Inc.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. GenScript Biotech Corporation
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Guardant Health, Inc.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Helomics Corporation
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. HistoGeneX NV
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. HTG Molecular Diagnostics, Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Illumina, Inc.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. NanoString Technologies, Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. NeoGenomics Laboratories, Inc.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Omniseq, Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Perthera, Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. QIAGEN N.V.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Ribomed Biotechnologies, Inc.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Roche Diagnostics
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Sysmex Corporation
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Tempus Labs
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing